Type and hit ENTER

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing client list of pharmaceutical companies and academic laboratories.

ProAxsis specialises in four key areas of business:

ProteaseTag®
Active Neutrophil Elastase Immunoassay
  • Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.
NEATstik®
Neutrophil Elastase Airways Test
  • Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.
Clinical research services
services for both academic and pharmaceutical company researchers
  • Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.
R&D Projects
are supported by a variety of external partners
  • ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners. We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.
Image Not Found On Media Library

ProteaseTag® immunoassay - Activity-based immunoassay kits

Activity-based immunoassay kits – Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.
Image Not Found On Media Library

Rapid point-of-care tests – NEATstik®

Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.

Activity-based immunoassay kits

Activity-based immunoassay kits – Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.

Rapid point-of-care tests – NEATstik®

Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.

Clinical research services

Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.

R&D Projects

ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners. We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.

Welcome to ProAxsis

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease, using its patented ProteaseTag® technology.

ProAxsis specialises in four key areas of business:-

  • Activity-based immunoassay kits – Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.

 

  • Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.

 

  • Clinical research services – Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.

 

  • R&D Projects – ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners.  We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.

ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, today announces that it has appointed Diapharma Group Inc. as the exclusive distributor of its portfolio of respiratory research assays for the North America region. Based in Ohio, Diapharma …

November 19, 2020

ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, today announces a significant change to its investor base. Netscientific, who previously held a 56.4% equity share of ProAxsis, have taken full control of the company through acquisition of all …

October 16, 2020

ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been awarded an Innovate UK grant as part of the “business-led innovation in response to global disruption” scheme, which was set up in light of the COVID-19 pandemic.  The £50,000 award will be utilised to …

August 3, 2020
GET CONNECTED
RECENT POSTS
ABOUT ME
LIFESTYLE
SHOP ONLINE
old Home | ProAxsis